ReviewThe world journal of men's health2021
Novel Emerging Therapies for Erectile Dysfunction.
Review in The world journal of men's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Medicinal Plants Used for the Treatment of Erectile Dysfunction in Ethiopia: A Systematic Review.BioMed research international · 2021Pooled it
- The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial.Frontiers in endocrinology · 2022Trial
- Slit2/Robo Signaling Restores Diabetic Erectile Function via Neurovascular Remodeling.Andrology · 2026Article
- Differences in adipose-derived stem cells from rats with various health statuses and their effects in diabetic rats with erectile dysfunction.Asian journal of andrology · 2026Article
- Implantable pelvic neurostimulators to restore erectile function: from concept to practice.Nature reviews. Urology · 2026Review
- Intracavernosal Botulinum Toxin Injection for Erectile Dysfunction: A Comprehensive Systematic Review.Life (Basel, Switzerland) · 2025Review
- The role of programmed cell death in diabetes mellitus-induced erectile dysfunction: from mechanisms to targeted therapy.Reproductive biology and endocrinology : RB&E · 2025Review
- Investigation of Cissus populnea as a Potential Therapeutic Agent for Erectile Dysfunction.Cell biochemistry and biophysics · 2025Article
- Association of Sexual Health and Mental Health in Erectile Dysfunction: Expert Opinion From the Indian Context.Cureus · 2025Review
- Review
- An update on the use of stem cell therapy for erectile dysfunction.Asian journal of urology · 2024Review
- Nitro-oleic acid (NOTranslational andrology and urology · 2024Article
- Addressing the need for preclinical study of penile prosthesis infection: a new animal model and narrative review.Translational andrology and urology · 2024Review
- Reviving intimacy: Penile rehabilitation strategies for men after prostate cancer treatment.Prostate international · 2023Review
- Erectile dysfunction and exosome therapy.Frontiers in endocrinology · 2023Review
- Management of male erectile dysfunction: From the past to the future.Frontiers in endocrinology · 2023Review
- Heat Shock Protein 70 in Penile Neurovascular Regeneration Requires Cystathionine Gamma-Lyase.The world journal of men's health · 2022Article
- An EPO-loaded multifunctional hydrogel synergizing with adipose-derived stem cells restores neurogenic erectile function via enhancing nerve regeneration and penile rehabilitation.Bioengineering & translational medicine · 2022Article
- Efficacy of Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Chronic Pelvic Pain Syndrome IIIb: A Prospective-Randomized, Double-Blind, Placebo-Controlled Study.The world journal of men's health · 2022Article
- Aphrodisiac Performance of Bioactive Compounds fromMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, several treatments exist for the improvement of erectile dysfunction (ED). These include medical therapies such as phosphodiesterase type 5 inhibitors (PDE5-Is), invasive methods such as intracavernosal injection therapy of vaso-active substances, vacuum erection devices, and penile prosthesis implants. However, the percentage of patients that are unresponsive to available treatments and who drop out from treatments remains high. Current evidence reveals that the pathogenesis of ED is related to multiple factors including underlying comorbidities, previous surgery, and psychological factors. Diverse approaches using novel molecular pathways or new technologies have been tested as potential therapeutic options for difficultto-treat ED populations. Melanocortin receptor agonist, a centrally acting agent, showed promising results by initiating erection without sexual stimulation in non-responders to PDE5-Is. Recent clinical and pre-clinical studies using human tissues suggested that new peripherally acting agents including the Max-K channel activator, guanylate cyclase activator, and nitric oxide donor could be potential therapies either as a monotherapy or in combination with PDE5-Is in ED patients. According to several clinical trials, regeneration therapy using stem cells showed favorable data in men with diabetic or post-prostatectomy ED. Low-intensity shock wave therapy also demonstrated promising results in patients with vasculogenic ED. There are growing evidences which suggest the efficacy of these emerging therapies, though most of the therapies still need to be validated by well-designed clinical trials. It is expected that, should their long-term safety and efficacy be proven, the emerging treatments can meet the needs of patients hitherto unresponsive to or unsatisfied by current therapies for ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.